Profusa's Lumee Sensor Shows Promise in Long-Term PAD Monitoring
Event summary
- Profusa presented positive US-study clinical results for its Lumee oxygen tissue monitoring system at LINC 2026 on January 28, 2026.
- The study, conducted at three US sites, showed strong correlation between Lumee sensors and traditional tcpO2 measurements in PAD patients.
- Sensors remained functional for up to one year with no reported adverse events.
- Profusa expects to generate $0.5 to $2 million in revenue in 2026, with EU commercial activities commencing in 2Q 2026.
The big picture
Profusa's positive clinical results for its Lumee sensor in PAD patients mark a significant step in the continuous monitoring of chronic diseases. The strong correlation with traditional methods and long-term functionality data position the company favorably as it expands into the European market. The digital health sector is increasingly focused on remote monitoring solutions, and Profusa's technology could become a key player if it can sustain its clinical validation and commercial execution.
What we're watching
- Market Expansion
- Whether Profusa can successfully execute its commercial strategies in the European Union and meet its revenue targets.
- Technology Validation
- How the clinical community will respond to the long-term functionality and safety data of Lumee sensors.
- Competitive Positioning
- The pace at which Profusa can differentiate itself in the continuous monitoring space against traditional tcpO2 methods.